Will the FDA approve a cure for Type 1 diabetes before 2033?
As of Fri, 20 Nov 2026 21:57:27 UTC, Kalshi traders price Yes (41.0%). The market has $11K in volume and closes on Sat, 01 Jan 2033.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Yes | 41.0% | 41.0¢ | 59.0¢ |
Market details
- Venue: Kalshi
- Volume: $11K
- Liquidity: $11K
- Closes:
Resolution rules
If the FDA approves a cure for Type 1 diabetes before Jan 1, 2033, then the market resolves to Yes.
Sources
Related markets
- When will the FDA reclassify BPC-157 to Category 1?
- Will the FDA approve retatrutide?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- Will the U.S. confirm that aliens exist?
- Best AI at the end of 2026?
- When will Anthropic release Mythos?
More markets like this
- Will the FDA approve CagriSema?
- Will the FDA approve VERVE-102?
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)
- FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)
- Will the FDA approve any psychedelic substance for medical use this year?
- Will the OpenAI/Jony Ive device have a screen?
- Will the South Carolina special Republican primary be won outright?
- Will the US start the process of building a nuclear-powered data center on a military base before 2030?
A price on DOXA is the market-implied probability of an outcome on the venue that lists it. It is what traders are paying, not a forecast made by DOXA, and it is not investment advice. How DOXA shows prices · Terms of Use
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.